Contrasting effects of sunitinib within in vivo models of metastasis

Jonathan C. Welti, Thomas Powles, Shane Foo, Morgane Gourlaouen, Natasha Preece, Julie Foster, Sophia Frentzas, Demelza Bird, Kevin Sharpe, Antoinette Van Weverwijk, David Robertson, Julie Soffe, Janine T. Erler, Roberto Pili, Caroline J. Springer, Stephen J. Mather, Andrew R. Reynolds

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Sunitinib is a potent and clinically approved tyrosine kinase inhibitor that can suppress tumour growth by inhibiting angiogenesis. However, conflicting data exist regarding the effects of this drug on the growth of metastases in preclinical models. Here we use 4T1 and RENCA tumour cells, which both form lung metastases in Balb/c mice, to re-address the effects of sunitinib on the progression of metastatic disease in mice. We show that treatment of mice with sunitinib prior to intravenous injection of tumour cells can promote the seeding and growth of 4T1 lung metastases, but not RENCA lung metastases, showing that this effect is cell line dependent. However, increased metastasis occurred only upon administration of a very high sunitinib dose, but not when lower, clinically relevant doses were used. Mechanistically, high dose sunitinib led to a pericyte depletion effect in the lung vasculature that correlated with increased seeding of metastasis. By administering sunitinib to mice after intravenous injection of tumour cells, we demonstrate that while sunitinib does not inhibit the growth of 4T1 lung tumour nodules, it does block the growth of RENCA lung tumour nodules. This contrasting response was correlated with increased myeloid cell recruitment and persistent vascularisation in 4T1 tumours, whereas RENCA tumours recruited less myeloid cells and were more profoundly devascularised upon sunitinib treatment. Finally, we show that progression of 4T1 tumours in sunitinib treated mice results in increased hypoxia and increased glucose metabolism in these tumours and that this is associated with a poor outcome. Taken together, these data suggest that the effects of sunitinib on tumour progression are dosedependent and tumour model-dependent. These findings have relevance for understanding how anti-angiogenic agents may influence disease progression when used in the adjuvant or metastatic setting in cancer patients.

Original languageEnglish (US)
Pages (from-to)623-641
Number of pages19
JournalAngiogenesis
Volume15
Issue number4
DOIs
StatePublished - 2012
Externally publishedYes

Fingerprint

Tumors
Neoplasm Metastasis
Neoplasms
Lung
Cells
Growth
Myeloid Cells
Intravenous Injections
sunitinib
Disease Progression
Pericytes
Metabolism
Protein-Tyrosine Kinases
Glucose
Cell Line

Keywords

  • Angiogenesis
  • Breast
  • Metastasis
  • Renal
  • Resistance
  • VEGF

ASJC Scopus subject areas

  • Cancer Research
  • Physiology
  • Clinical Biochemistry

Cite this

Welti, J. C., Powles, T., Foo, S., Gourlaouen, M., Preece, N., Foster, J., ... Reynolds, A. R. (2012). Contrasting effects of sunitinib within in vivo models of metastasis. Angiogenesis, 15(4), 623-641. https://doi.org/10.1007/s10456-012-9291-z

Contrasting effects of sunitinib within in vivo models of metastasis. / Welti, Jonathan C.; Powles, Thomas; Foo, Shane; Gourlaouen, Morgane; Preece, Natasha; Foster, Julie; Frentzas, Sophia; Bird, Demelza; Sharpe, Kevin; Weverwijk, Antoinette Van; Robertson, David; Soffe, Julie; Erler, Janine T.; Pili, Roberto; Springer, Caroline J.; Mather, Stephen J.; Reynolds, Andrew R.

In: Angiogenesis, Vol. 15, No. 4, 2012, p. 623-641.

Research output: Contribution to journalArticle

Welti, JC, Powles, T, Foo, S, Gourlaouen, M, Preece, N, Foster, J, Frentzas, S, Bird, D, Sharpe, K, Weverwijk, AV, Robertson, D, Soffe, J, Erler, JT, Pili, R, Springer, CJ, Mather, SJ & Reynolds, AR 2012, 'Contrasting effects of sunitinib within in vivo models of metastasis', Angiogenesis, vol. 15, no. 4, pp. 623-641. https://doi.org/10.1007/s10456-012-9291-z
Welti JC, Powles T, Foo S, Gourlaouen M, Preece N, Foster J et al. Contrasting effects of sunitinib within in vivo models of metastasis. Angiogenesis. 2012;15(4):623-641. https://doi.org/10.1007/s10456-012-9291-z
Welti, Jonathan C. ; Powles, Thomas ; Foo, Shane ; Gourlaouen, Morgane ; Preece, Natasha ; Foster, Julie ; Frentzas, Sophia ; Bird, Demelza ; Sharpe, Kevin ; Weverwijk, Antoinette Van ; Robertson, David ; Soffe, Julie ; Erler, Janine T. ; Pili, Roberto ; Springer, Caroline J. ; Mather, Stephen J. ; Reynolds, Andrew R. / Contrasting effects of sunitinib within in vivo models of metastasis. In: Angiogenesis. 2012 ; Vol. 15, No. 4. pp. 623-641.
@article{70ff0bc3d3db4176a44feb38ab389be8,
title = "Contrasting effects of sunitinib within in vivo models of metastasis",
abstract = "Sunitinib is a potent and clinically approved tyrosine kinase inhibitor that can suppress tumour growth by inhibiting angiogenesis. However, conflicting data exist regarding the effects of this drug on the growth of metastases in preclinical models. Here we use 4T1 and RENCA tumour cells, which both form lung metastases in Balb/c mice, to re-address the effects of sunitinib on the progression of metastatic disease in mice. We show that treatment of mice with sunitinib prior to intravenous injection of tumour cells can promote the seeding and growth of 4T1 lung metastases, but not RENCA lung metastases, showing that this effect is cell line dependent. However, increased metastasis occurred only upon administration of a very high sunitinib dose, but not when lower, clinically relevant doses were used. Mechanistically, high dose sunitinib led to a pericyte depletion effect in the lung vasculature that correlated with increased seeding of metastasis. By administering sunitinib to mice after intravenous injection of tumour cells, we demonstrate that while sunitinib does not inhibit the growth of 4T1 lung tumour nodules, it does block the growth of RENCA lung tumour nodules. This contrasting response was correlated with increased myeloid cell recruitment and persistent vascularisation in 4T1 tumours, whereas RENCA tumours recruited less myeloid cells and were more profoundly devascularised upon sunitinib treatment. Finally, we show that progression of 4T1 tumours in sunitinib treated mice results in increased hypoxia and increased glucose metabolism in these tumours and that this is associated with a poor outcome. Taken together, these data suggest that the effects of sunitinib on tumour progression are dosedependent and tumour model-dependent. These findings have relevance for understanding how anti-angiogenic agents may influence disease progression when used in the adjuvant or metastatic setting in cancer patients.",
keywords = "Angiogenesis, Breast, Metastasis, Renal, Resistance, VEGF",
author = "Welti, {Jonathan C.} and Thomas Powles and Shane Foo and Morgane Gourlaouen and Natasha Preece and Julie Foster and Sophia Frentzas and Demelza Bird and Kevin Sharpe and Weverwijk, {Antoinette Van} and David Robertson and Julie Soffe and Erler, {Janine T.} and Roberto Pili and Springer, {Caroline J.} and Mather, {Stephen J.} and Reynolds, {Andrew R.}",
year = "2012",
doi = "10.1007/s10456-012-9291-z",
language = "English (US)",
volume = "15",
pages = "623--641",
journal = "Angiogenesis",
issn = "0969-6970",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - Contrasting effects of sunitinib within in vivo models of metastasis

AU - Welti, Jonathan C.

AU - Powles, Thomas

AU - Foo, Shane

AU - Gourlaouen, Morgane

AU - Preece, Natasha

AU - Foster, Julie

AU - Frentzas, Sophia

AU - Bird, Demelza

AU - Sharpe, Kevin

AU - Weverwijk, Antoinette Van

AU - Robertson, David

AU - Soffe, Julie

AU - Erler, Janine T.

AU - Pili, Roberto

AU - Springer, Caroline J.

AU - Mather, Stephen J.

AU - Reynolds, Andrew R.

PY - 2012

Y1 - 2012

N2 - Sunitinib is a potent and clinically approved tyrosine kinase inhibitor that can suppress tumour growth by inhibiting angiogenesis. However, conflicting data exist regarding the effects of this drug on the growth of metastases in preclinical models. Here we use 4T1 and RENCA tumour cells, which both form lung metastases in Balb/c mice, to re-address the effects of sunitinib on the progression of metastatic disease in mice. We show that treatment of mice with sunitinib prior to intravenous injection of tumour cells can promote the seeding and growth of 4T1 lung metastases, but not RENCA lung metastases, showing that this effect is cell line dependent. However, increased metastasis occurred only upon administration of a very high sunitinib dose, but not when lower, clinically relevant doses were used. Mechanistically, high dose sunitinib led to a pericyte depletion effect in the lung vasculature that correlated with increased seeding of metastasis. By administering sunitinib to mice after intravenous injection of tumour cells, we demonstrate that while sunitinib does not inhibit the growth of 4T1 lung tumour nodules, it does block the growth of RENCA lung tumour nodules. This contrasting response was correlated with increased myeloid cell recruitment and persistent vascularisation in 4T1 tumours, whereas RENCA tumours recruited less myeloid cells and were more profoundly devascularised upon sunitinib treatment. Finally, we show that progression of 4T1 tumours in sunitinib treated mice results in increased hypoxia and increased glucose metabolism in these tumours and that this is associated with a poor outcome. Taken together, these data suggest that the effects of sunitinib on tumour progression are dosedependent and tumour model-dependent. These findings have relevance for understanding how anti-angiogenic agents may influence disease progression when used in the adjuvant or metastatic setting in cancer patients.

AB - Sunitinib is a potent and clinically approved tyrosine kinase inhibitor that can suppress tumour growth by inhibiting angiogenesis. However, conflicting data exist regarding the effects of this drug on the growth of metastases in preclinical models. Here we use 4T1 and RENCA tumour cells, which both form lung metastases in Balb/c mice, to re-address the effects of sunitinib on the progression of metastatic disease in mice. We show that treatment of mice with sunitinib prior to intravenous injection of tumour cells can promote the seeding and growth of 4T1 lung metastases, but not RENCA lung metastases, showing that this effect is cell line dependent. However, increased metastasis occurred only upon administration of a very high sunitinib dose, but not when lower, clinically relevant doses were used. Mechanistically, high dose sunitinib led to a pericyte depletion effect in the lung vasculature that correlated with increased seeding of metastasis. By administering sunitinib to mice after intravenous injection of tumour cells, we demonstrate that while sunitinib does not inhibit the growth of 4T1 lung tumour nodules, it does block the growth of RENCA lung tumour nodules. This contrasting response was correlated with increased myeloid cell recruitment and persistent vascularisation in 4T1 tumours, whereas RENCA tumours recruited less myeloid cells and were more profoundly devascularised upon sunitinib treatment. Finally, we show that progression of 4T1 tumours in sunitinib treated mice results in increased hypoxia and increased glucose metabolism in these tumours and that this is associated with a poor outcome. Taken together, these data suggest that the effects of sunitinib on tumour progression are dosedependent and tumour model-dependent. These findings have relevance for understanding how anti-angiogenic agents may influence disease progression when used in the adjuvant or metastatic setting in cancer patients.

KW - Angiogenesis

KW - Breast

KW - Metastasis

KW - Renal

KW - Resistance

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84875051632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875051632&partnerID=8YFLogxK

U2 - 10.1007/s10456-012-9291-z

DO - 10.1007/s10456-012-9291-z

M3 - Article

VL - 15

SP - 623

EP - 641

JO - Angiogenesis

JF - Angiogenesis

SN - 0969-6970

IS - 4

ER -